🇺🇸 FDA
Pipeline program

XP19986 CR

XP-B-049

Phase 2 small_molecule completed

Quick answer

XP19986 CR for GERD is a Phase 2 program (small_molecule) at Indivior Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Indivior Pharmaceuticals
Indication
GERD
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials